Key PointsQuestionDoes intravenous alteplase benefit patients with ischemic stroke presenting with minor neurologic deficits that are judged not clearly disabling? FindingsIn this randomized clinical trial that included 313 of a planned 948 patients with acute ischemic stroke, there was no significant difference in the adjusted percentage with favorable functional outcome at 90 days for those treated with alteplase vs aspirin (78% vs 81%). MeaningAlthough the study did not demonstrate a significant benefit of alteplase for patients with minor nondisabling acute ischemic stroke, the very early study termination precludes any definitive conclusions.
JAMA – American Medical Association
Published: Jul 10, 2018